Adaptimmune Therapeutics PLC - Company Profile (NASDAQ:ADAP)

About Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)

Adaptimmune Therapeutics PLC - logoAdaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The Company is developing multiple SPEAR T-cells to different target peptides in selected disease indications to increase the probability of treating patients with a given disease indication and potentially the ability for re-treatment of patients with a different SPEAR T-cell. It has three SPEAR T-cells in clinical trials, which are directed to cancer testis antigens, NY-ESO-1, MAGE-A4 and MAGE-A10.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ADAP
  • CUSIP: N/A
  • Web: www.adaptimmune.com
Capitalization:
  • Market Cap: $495.53 million
  • Outstanding Shares: 93,496,000
Average Prices:
  • 50 Day Moving Avg: $5.40
  • 200 Day Moving Avg: $4.68
  • 52 Week Range: $3.76 - $11.59
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.86
  • P/E Growth: 0.12
Sales & Book Value:
  • Annual Revenue: $14.14 million
  • Price / Sales: 35.04
  • Book Value: $2.41 per share
  • Price / Book: 2.20
Profitability:
  • EBIDTA: ($74,610,000.00)
  • Net Margins: -667.22%
  • Return on Equity: -31.56%
  • Return on Assets: -25.90%
Debt:
  • Current Ratio: 8.81%
  • Quick Ratio: 8.81%
Misc:
  • Average Volume: 290,032 shs.
  • Beta: 1.46
  • Short Ratio: 0.73
 

Frequently Asked Questions for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)

What is Adaptimmune Therapeutics PLC -'s stock symbol?

Adaptimmune Therapeutics PLC - trades on the NASDAQ under the ticker symbol "ADAP."

How were Adaptimmune Therapeutics PLC -'s earnings last quarter?

Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) announced its earnings results on Wednesday, May, 10th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.24) by $0.06. The company had revenue of $2.86 million for the quarter, compared to analyst estimates of $5.07 million. Adaptimmune Therapeutics PLC - had a negative return on equity of 31.56% and a negative net margin of 667.22%. View Adaptimmune Therapeutics PLC -'s Earnings History.

Where is Adaptimmune Therapeutics PLC -'s stock going? Where will Adaptimmune Therapeutics PLC -'s stock price be in 2017?

5 brokerages have issued twelve-month target prices for Adaptimmune Therapeutics PLC -'s stock. Their forecasts range from $15.00 to $16.00. On average, they expect Adaptimmune Therapeutics PLC -'s stock price to reach $15.50 in the next year. View Analyst Ratings for Adaptimmune Therapeutics PLC -.

Who are some of Adaptimmune Therapeutics PLC -'s key competitors?

When did Adaptimmune Therapeutics PLC - IPO?

(ADAP) raised $150 million in an IPO on Wednesday, May 6th 2015. The company issued 9,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

Who owns Adaptimmune Therapeutics PLC - stock?

Adaptimmune Therapeutics PLC -'s stock is owned by many different of institutional and retail investors. Top institutional investors include NEA Management Company LLC (0.00%), FMR LLC (0.00%), Tekla Capital Management LLC (0.00%), Baillie Gifford & Co. (0.00%), AXA (0.00%) and Renaissance Technologies LLC (0.00%). Company insiders that own Adaptimmune Therapeutics PLC - stock include Charles Elliott Sigal, Enterprise Associates 14 New and Orbimed Advisors Llc. View Institutional Ownership Trends for Adaptimmune Therapeutics PLC -.

Who sold Adaptimmune Therapeutics PLC - stock? Who is selling Adaptimmune Therapeutics PLC - stock?

Adaptimmune Therapeutics PLC -'s stock was sold by a variety of institutional investors in the last quarter, including FMR LLC and JPMorgan Chase & Co.. View Insider Buying and Selling for Adaptimmune Therapeutics PLC -.

Who bought Adaptimmune Therapeutics PLC - stock? Who is buying Adaptimmune Therapeutics PLC - stock?

Adaptimmune Therapeutics PLC -'s stock was acquired by a variety of institutional investors in the last quarter, including NEA Management Company LLC, AXA, Tekla Capital Management LLC, Point72 Asset Management L.P., Renaissance Technologies LLC, Granite Investment Partners LLC, Wellington Management Group LLP and Essex Investment Management Co. LLC. Company insiders that have bought Adaptimmune Therapeutics PLC - stock in the last two years include Charles Elliott Sigal, Enterprise Associates 14 New and Orbimed Advisors Llc. View Insider Buying and Selling for Adaptimmune Therapeutics PLC -.

How do I buy Adaptimmune Therapeutics PLC - stock?

Shares of Adaptimmune Therapeutics PLC - can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Adaptimmune Therapeutics PLC - stock cost?

One share of Adaptimmune Therapeutics PLC - stock can currently be purchased for approximately $5.30.

Analyst Ratings

Consensus Ratings for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) (?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.40)
Consensus Price Target: $15.50 (192.45% upside)

Analysts' Ratings History for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/17/2017Wells Fargo & CoInitiated CoverageMarket Perform -> Market PerformLowView Rating Details
11/11/2016Leerink SwannReiterated RatingBuy$15.00N/AView Rating Details
11/10/2016Cowen and CompanyReiterated RatingBuyN/AView Rating Details
10/24/2016Bank of America CorpDowngradeNeutral -> UnderperformN/AView Rating Details
9/30/2016Raymond James Financial, Inc.Initiated CoverageOutperform$16.00N/AView Rating Details
2/27/2016Deutsche Bank AGInitiated CoverageBuyN/AView Rating Details
2/25/2016Citigroup IncInitiated CoverageBuy$15.00N/AView Rating Details
12/22/2015SunTrust Banks, Inc.Initiated CoverageBuy$16.00N/AView Rating Details
6/1/2015GuggenheimInitiated CoverageBuy$25.00N/AView Rating Details
(Data available from 5/26/2015 forward)

Earnings

Earnings History for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
Earnings by Quarter for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
Earnings History by Quarter for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/20173/31/2017($0.24)($0.30)$5.07 million$2.86 millionViewN/AView Earnings Details
3/13/201712/31/2016($0.27)($0.22)$3.98 million$8.54 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
2017 EPS Consensus Estimate: ($1.04)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.27)($0.24)($0.26)
Q2 20172($0.26)($0.24)($0.25)
Q3 20172($0.27)($0.25)($0.26)
Q4 20172($0.29)($0.25)($0.27)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
Institutional Ownership Percentage: 43.67%
Insider Trades by Quarter for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
Institutional Ownership by Quarter for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
Insider Trades by Quarter for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/27/2017Enterprise Associates 14 NewMajor ShareholderBuy12,870,000$0.70$9,009,000.00View SEC Filing  
3/27/2017Orbimed Advisors LlcDirectorBuy1,190,476$4.20$4,999,999.20View SEC Filing  
5/24/2016Orbimed Advisors LlcDirectorBuy1,712,400$10.42$17,843,208.00View SEC Filing  
5/19/2016Charles Elliott SigalDirectorBuy15,000$1.56$23,400.00View SEC Filing  
5/18/2016Charles Elliott SigalDirectorBuy45,000$1.53$68,850.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
Latest Headlines for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
Source:
DateHeadline
globenewswire.com logoAdaptimmune Announces Initiation of Study to Evaluate SPEAR T ... - GlobeNewswire (press release)
globenewswire.com - May 25 at 3:36 PM
finance.yahoo.com logoAdaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting NY-ESO in Combination with KEYTRUDA® (pembrolizumab) in Multiple Myeloma
finance.yahoo.com - May 25 at 3:36 PM
reuters.com logoBRIEF-Adaptimmune reports initiation of study to evaluate spear t-cell therapy
www.reuters.com - May 16 at 8:20 PM
finance.yahoo.com logoAdaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting MAGE-A4 in Multiple Solid Tumors
finance.yahoo.com - May 16 at 3:20 PM
americanbankingnews.com logoAdaptimmune Therapeutics PLC - Forecasted to Earn Q2 2017 Earnings of ($0.24) Per Share (ADAP)
www.americanbankingnews.com - May 12 at 10:42 AM
americanbankingnews.com logoAdaptimmune Therapeutics PLC - (ADAP) Announces Earnings Results, Misses Expectations By $0.06 EPS
www.americanbankingnews.com - May 11 at 5:12 PM
reuters.com logoBRIEF-Adaptimmune Q1 loss per share $0.05
www.reuters.com - May 10 at 8:26 PM
streetinsider.com logoAdaptimmune Therapeutics (ADAP) Begins Study on SPEAR T-Cell ... - StreetInsider.com
www.streetinsider.com - May 10 at 3:26 PM
streetinsider.com logoAdaptimmune Therapeutics (ADAP) Begins Study on SPEAR T-Cell Therapy Targeting AFP in Liver Cancer
www.streetinsider.com - May 10 at 9:36 AM
finance.yahoo.com logoAdaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting AFP in Liver Cancer
finance.yahoo.com - May 10 at 9:36 AM
finance.yahoo.com logoAdaptimmune Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 10 at 9:36 AM
americanbankingnews.com logoAdaptimmune Therapeutics PLC - (ADAP) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - May 8 at 10:08 AM
americanbankingnews.com logoAdaptimmune Therapeutics PLC - (ADAP) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 8 at 8:15 AM
finance.yahoo.com logoAdaptimmune to Report First Quarter 2017 Financial Results on May 10, 2017
finance.yahoo.com - May 3 at 8:28 PM
americanbankingnews.com logoAdaptimmune Therapeutics PLC - (ADAP) Earns Coverage Optimism Rating of 0.03
www.americanbankingnews.com - May 3 at 8:30 AM
finance.yahoo.com logoAdaptimmune to Present at Upcoming Deutsche Bank 42nd Annual Health Care Conference - Yahoo Finance
finance.yahoo.com - May 3 at 6:45 AM
americanbankingnews.com logoAdaptimmune Therapeutics PLC - (ADAP) Getting Somewhat Favorable Media Coverage, Analysis Finds
www.americanbankingnews.com - April 30 at 11:18 AM
americanbankingnews.com logoZacks: Brokerages Anticipate Adaptimmune Therapeutics PLC - (ADAP) to Post -$0.26 Earnings Per Share
www.americanbankingnews.com - April 28 at 12:48 AM
americanbankingnews.com logoAdaptimmune Therapeutics PLC - (ADAP) Earning Somewhat Negative Media Coverage, Analysis Shows
www.americanbankingnews.com - April 27 at 9:32 AM
americanbankingnews.com logoAdaptimmune Therapeutics PLC - (ADAP) Earning Favorable Press Coverage, Analysis Finds
www.americanbankingnews.com - April 21 at 8:19 AM
americanbankingnews.com logoAdaptimmune Therapeutics PLC - (ADAP) Receives Daily News Impact Score of 0.56
www.americanbankingnews.com - April 15 at 8:23 AM
nasdaq.com logoAdaptimmune Therapeutics plc Announces Closing of $42 Million Registered Direct Offering - Nasdaq
www.nasdaq.com - April 11 at 8:25 AM
globenewswire.com logoAdaptimmune Therapeutics plc Announces Closing of $42 Million Registered Direct Offering - GlobeNewswire (press release)
www.globenewswire.com - April 10 at 3:18 PM
finance.yahoo.com logoAdaptimmune Therapeutics plc Announces Closing of $42 Million Registered Direct Offering
finance.yahoo.com - April 10 at 3:18 PM
americanbankingnews.com logo$5.07 Million in Sales Expected for Adaptimmune Therapeutics PLC - (ADAP) This Quarter
www.americanbankingnews.com - April 8 at 9:02 AM
reuters.com logoBRIEF-Adaptimmune Therapeutics announces registered direct offering of ADS
www.reuters.com - April 7 at 8:18 PM
globenewswire.com logoAdaptimmune Therapeutics plc Announces Registered Direct Offering of American Depositary Shares - GlobeNewswire (press release)
globenewswire.com - April 7 at 6:02 AM
finance.yahoo.com logoAdaptimmune Therapeutics plc Announces Registered Direct Offering of American Depositary Shares
finance.yahoo.com - April 7 at 6:02 AM
americanbankingnews.com logo Brokerages Anticipate Adaptimmune Therapeutics PLC - (ADAP) to Post -$0.26 EPS
www.americanbankingnews.com - April 6 at 8:21 PM
americanbankingnews.com logoAdaptimmune Therapeutics PLC - (ADAP) Sees Significant Decrease in Short Interest
www.americanbankingnews.com - April 4 at 3:48 PM
streetinsider.com logoForm 8-K Adaptimmune Therapeutics For: Mar 27 - StreetInsider.com
www.streetinsider.com - March 30 at 3:42 PM
americanbankingnews.com logoInsider Buying: Adaptimmune Therapeutics PLC - (ADAP) Director Purchases 1,190,476 Shares of Stock
www.americanbankingnews.com - March 29 at 9:11 AM
americanbankingnews.com logoAdaptimmune Therapeutics PLC - (ADAP) Major Shareholder Enterprise Associates 14 New Purchases 12,870,000 Shares
www.americanbankingnews.com - March 29 at 9:10 AM
globenewswire.com logoAdaptimmune Therapeutics plc Announces Closing of Public Offering and Exercise of Underwriters' Option to Purchase ... - GlobeNewswire (press release)
globenewswire.com - March 28 at 3:18 PM
nasdaq.com logoAdaptimmune Therapeutics plc Announces Closing of Public Offering and Exercise ...
www.nasdaq.com - March 27 at 3:29 PM
finance.yahoo.com logoAdaptimmune Therapeutics plc Announces Closing of Public Offering and Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
finance.yahoo.com - March 27 at 3:29 PM
finance.yahoo.com logoAdaptimmune Therapeutics plc Announces Closing of Public Offering and Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
finance.yahoo.com - March 27 at 3:29 PM
finance.yahoo.com logoAdaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares - Yahoo Finance
finance.yahoo.com - March 23 at 11:38 PM
reuters.com logoBRIEF-Adaptimmune Therapeutics prices public offering of American Depositary Shares
www.reuters.com - March 22 at 8:21 PM
biz.yahoo.com logoADAPTIMMUNE THERAPEUTICS PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial
biz.yahoo.com - March 22 at 8:21 PM
finance.yahoo.com logoAdaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares
finance.yahoo.com - March 22 at 3:20 PM
reuters.com logoBRIEF-Adaptimmune Therapeutics proposes public offering of American Depositary Shares
www.reuters.com - March 21 at 8:38 PM
finanznachrichten.de logoAdaptimmune Therapeutics plc: Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
www.finanznachrichten.de - March 21 at 8:38 PM
streetinsider.com logoAdaptimmune Therapeutics (ADAP) Plans Offering of American Depositary Shares
www.streetinsider.com - March 21 at 8:38 PM
finance.yahoo.com logoAdaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
finance.yahoo.com - March 21 at 8:38 PM
finance.yahoo.com logoCoverage initiated on Adaptimmune Therapeutics by Wells Fargo
finance.yahoo.com - March 18 at 1:42 AM
reuters.com logoBRIEF-Adaptimmune Therapeutics names Helen Tayton-Martin as chief business officer
www.reuters.com - March 16 at 4:49 PM
finance.yahoo.com logoADAPTIMMUNE THERAPEUTICS PLC Financials
finance.yahoo.com - March 16 at 4:49 PM
us.rd.yahoo.com logo7:30 am Adaptimmune Therapeutics appoints co-founder, Helen Tayton-Martin, Ph.D., M.B.A, to the newly-created role of Chief Business Officer, and William Bertrand, Jr., J.D., as COO, both effective immediately
us.rd.yahoo.com - March 15 at 8:24 PM
biz.yahoo.com logoADAPTIMMUNE THERAPEUTICS PLC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and
biz.yahoo.com - March 15 at 8:24 PM

Social

Chart

Adaptimmune Therapeutics PLC - (ADAP) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by MarketBeat.com Staff